Hexvix (Hexaminolevulinate)

Hexvix is indicated for the photodynamic diagnosis of non‑muscle invasive bladder cancer during cystoscopic evaluation.

• Detection of carcinoma in situ (CIS) and papillary tumors during blue‑light cystoscopy.
• Adjunct to white‑light cystoscopy to improve lesion visibility.
• Assessment of tumor margins after transurethral resection.
• Guidance for targeted biopsies in suspicious areas.
• Use in surveillance cystoscopies to monitor recurrence.
• Evaluation of flat lesions that are difficult to visualize with conventional lighting.
• Facilitation of complete resection by highlighting residual disease after initial tumor removal.

• Hexvix contains hexaminolevulinate, a prodrug that enters urothelial cells and is metabolized in the heme biosynthetic pathway to protoporphyrin IX. Malignant cells preferentially accumulate protoporphyrin IX, which fluoresces when excited by blue light (around 405 nm). The resulting red‑orange fluorescence delineates cancerous tissue during cystoscopy, allowing visual differentiation from normal bladder mucosa. The selective accumulation is related to increased activity of enzymes such as porphobilinogen deaminase in tumor cells, enhancing the diagnostic contrast.

Adverse reactions reported with intravesical Hexvix are generally mild and related to the local administration, but rare serious events have been described.

Common

• Transient bladder irritation or burning sensation.
• Dysuria (painful urination) lasting a few hours.
• Mild hematuria (blood in urine) after the procedure.
• Urinary urgency or frequency.
• Low‑grade fever.
• Mild suprapubic discomfort during the dwell time.

Serious

• Acute allergic reaction including rash, pruritus, or angioedema.
• Severe bladder spasm or urinary retention requiring intervention.
• Systemic photosensitivity leading to skin reactions after exposure to strong light.
• Persistent hematuria or clot formation.
• Infection of the urinary tract (cystitis) secondary to instrumentation.
• Rare cases of bladder perforation associated with catheter placement.

Before using Hexvix, clinicians should evaluate patient history and procedural factors to minimize risks associated with intravesical administration.

• Confirm absence of active urinary tract infection prior to instillation.
• Ensure bladder capacity is adequate; avoid use in patients with severe obstruction or recent surgery.
• Review allergy history, especially to porphyrin compounds or similar photosensitizers.
• Advise patients to avoid direct exposure of the bladder to intense light sources for several hours after the procedure.
• Monitor for signs of urinary retention or severe irritation during the dwell period.
• Use caution in pregnant or breastfeeding women, as safety data are limited.

Hexvix is administered directly into the bladder, and systemic drug interactions are uncommon, but certain agents may affect its safety or diagnostic performance.

Avoid

• Concurrent use of strong photosensitizing drugs (e.g., porfimer sodium) that could amplify fluorescence or cause systemic photosensitivity.
• Intravesical instillation of other chemotherapeutic agents within 24 hours of Hexvix.
• Use in patients receiving systemic porphyrin precursors or heme synthesis modulators.
• Avoid exposure of the patient to intense ultraviolet light sources for at least 24 hours after the procedure to prevent systemic photosensitivity.

Use with caution

• Anticholinergic medications that may alter bladder contractility and affect dwell time.
• Antibiotics administered for prophylaxis, as they may mask signs of infection.
• Patients on anticoagulants, because hematuria may be more pronounced.
• Caution is advised when the patient has renal impairment, as altered excretion may influence local drug concentration.
• Monitor closely if the patient has a history of severe bladder irritation or prior allergic reactions to photosensitizers.